Fleury H - Search Results

1

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.

Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. Fierheller CT, et al. Among authors: fleury h. Genome Med. 2021 Dec 3;13(1):186. doi: 10.1186/s13073-021-00998-5. Genome Med. 2021. PMID: 34861889 Free PMC article.

2

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.

Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M. Marques M, et al. Among authors: fleury h. BMC Med. 2015 Sep 9;13:217. doi: 10.1186/s12916-015-0454-9. BMC Med. 2015. PMID: 26354718 Free PMC article.

3

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM. Fleury H, et al. Genes Cancer. 2015 Sep;6(9-10):378-398. doi: 10.18632/genesandcancer.76. Genes Cancer. 2015. PMID: 26622941 Free PMC article.

4

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Fleury H, et al. Oncotarget. 2017 Jun 20;8(25):40152-40168. doi: 10.18632/oncotarget.10308. Oncotarget. 2017. PMID: 27374179 Free PMC article.

5

Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.

Couturier AM, Fleury H, Patenaude AM, Bentley VL, Rodrigue A, Coulombe Y, Niraj J, Pauty J, Berman JN, Dellaire G, Di Noia JM, Mes-Masson AM, Masson JY. Couturier AM, et al. Among authors: fleury h. Nucleic Acids Res. 2016 Dec 15;44(22):10879-10897. doi: 10.1093/nar/gkw921. Epub 2016 Oct 24. Nucleic Acids Res. 2016. PMID: 27924011 Free PMC article.

6

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP. Wang YK, et al. Among authors: fleury h. Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24. Nat Genet. 2017. PMID: 28436987

7

Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution.

St-Georges-Robillard A, Cahuzac M, Péant B, Fleury H, Lateef MA, Ricard A, Sauriol A, Leblond F, Mes-Masson AM, Gervais T. St-Georges-Robillard A, et al. Among authors: fleury h. Integr Biol (Camb). 2019 Apr 1;11(4):130-141. doi: 10.1093/intbio/zyz012. Integr Biol (Camb). 2019. PMID: 31172192

8

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol SA, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F. Fleury H, et al. Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1. Nat Commun. 2019. PMID: 31186408 Free PMC article.

9

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.

Patra B, Lateef MA, Brodeur MN, Fleury H, Carmona E, Péant B, Provencher D, Mes-Masson AM, Gervais T. Patra B, et al. Among authors: fleury h. PLoS One. 2020 Dec 31;15(12):e0244549. doi: 10.1371/journal.pone.0244549. eCollection 2020. PLoS One. 2020. PMID: 33382759 Free PMC article.

10

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models.

Brodeur MN, Simeone K, Leclerc-Deslauniers K, Fleury H, Carmona E, Provencher DM, Mes-Masson AM. Brodeur MN, et al. Among authors: fleury h. Sci Rep. 2021 Sep 14;11(1):18183. doi: 10.1038/s41598-021-97434-w. Sci Rep. 2021. PMID: 34521878 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page